Eficacia y seguridad de la Ketamina en una paciente con depresión, síntomas psicóticos, enfermedad cardiovascular y riesgo de inanición


Autores/as

DOI:

https://doi.org/10.22517/25395203.24966

Palabras clave:

Ketamine, Depression

Resumen

Introduction: There has been a rising interest in ketamine as a promising treatment for refractory depression. Despite this, there is uncertain knowledge regarding aspects of the routinary use of ketamine for treating depression, such as optimal doses, long term toxicity, abuse potential in depressed patients, probable adverse effects associated with antidepressant drugs, the indication of ketamine in psychotic patients, and the ethical concerns of ketamine use.

Clinical case: A 63 year-old woman with a psychotic depressive episode, catatonic features, cardiovascular disease (patent foramen ovale and atrial fibrillation) , and starvation risk because she refused food intake. She was sent to electroconvulsive therapy (ECT) after several weeks of oral administration of benzodiazepine, antipsychotic, and antidepressant medications; the patient presented no improvement, but she was rejected due to her cardiovascular comorbidity. Two IV Ketamine doses were used as a life-saving strategy with good clinical response, mainly in terms of the catatonic features. The ketamine treatment was not only effective but also well tolerated.

Discussion: Despite the little information regarding its use in psychotic and catatonic patients, this case would suggest that it remains effective and safe, as well as a good option for patients with cardiovascular disease and those who cannot use electroconvulsive therapy.

Descargas

Los datos de descargas todavía no están disponibles.

Biografía del autor/a

Efraín Alberto Trejos Orozco, Universidad Tecnológica de Pereira

Estudiante de medicina

Julio César Gutiérrez Segura, Md., Universidad Tecnológica de Pereira

Médico

Especialista en psiquiatría

Especialista en psiquiatría de enlace

Docente titular, Universidad Tecnológica de Pereira

 

Sergio Andrés Ochoa Orozco, Md., Fundación Universitaria Autónoma de las Américas, Pereira, Risaralda

Médico

Especialista en psiquiatría

Docente, Fundación Universitaria Autónoma de las Américas

Citas

Singh I, Morgan C, Curran V, Nutt D, Schlag A, McShane R. Ketamine treatment for depression: opportunities for clinical innovation and ethical foresight. Lancet Psychiatry. 2017 May;4(5):419-426. doi: 10.1016/S2215-0366(17)30102-5

Short B, Fong J, Galvez V, Shelker W, Loo CK. Side-effects associated with ketamine use in depression: a systematic review. Lancet Psychiatry. 2018 Jan;5(1):65-78. doi: 10.1016/S2215-0366(17)30272-9.

Loo C. Can we confidently use ketamine as a clinical treatment for depression? Lancet Psychiatry. 2018 Jan;5(1):11-12. doi: 10.1016/S2215-0366(17)30480-7.

Blier P., Blier J. Ketamine: Clinical Studies in Treatment-Resistant Depressive Disorders. In: Mathew S., Zarate, Jr. C. (eds) Ketamine for Treatment-Resistant Depression. 2016. Adis, Cham. https://doi.org/10.1007/978-3-319-42925-0_3

Chang L.C., Rajagopalan S., Mathew S.J. (2016) The History of Ketamine Use and Its Clinical Indications. In: Mathew S., Zarate, Jr. C. (eds) Ketamine for Treatment-Resistant Depression. Adis, Cham. https://doi.org/10.1007/978-3-319-42925-0_1

Hermes G., Sanacora G. Ketamine’s Mechanisms of Rapid Antidepressant Activity: Evidence from Preclinical Studies. In: Mathew S., Zarate, Jr. C. (eds) Ketamine for Treatment-Resistant Depression. 2016. Adis, Cham. doi.org/10.1007/978-3-319-42925-0_6

Ballard E.D., Price R.B. (2016) Ketamine and Suicide Risk. In: Mathew S., Zarate, Jr. C. (eds) Ketamine for Treatment-Resistant Depression. 2016.Adis, Cham. doi.org/10.1007/978-3-319-42925-0_4

Bohórquez Peñaranda AP, García Valencia J, Rodríguez Guarín M, Arenas Borrero ÁE, Castro Díaz SM, de la Hoz Bradford AM, et al. Guía de atención integral para la detección temprana y diagnóstico del episodio depresivo y trastorno depresivo recurrente en adultos. Atención integral de los adultos con diagnóstico de episodio depresivo o trastorno depresivo recurrente. Parte III: Tratamiento de la depresión resistente y la depresión con psicosis, tratamiento con terapia ocupacional y hospital día. Revista Colombiana de Psiquiatría. 2012;41(4):774-86.

Descargas

Publicado

2022-02-14 — Actualizado el 2022-09-17

Versiones

Cómo citar

Trejos Orozco, E. A., Gutiérrez Segura, J. C., & Ochoa Orozco, S. A. (2022). Eficacia y seguridad de la Ketamina en una paciente con depresión, síntomas psicóticos, enfermedad cardiovascular y riesgo de inanición. Revista Médica De Risaralda, 28(1). https://doi.org/10.22517/25395203.24966 (Original work published 14 de febrero de 2022)

Número

Sección

Reporte de caso